Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCreo Medical Regulatory News (CREO)

Share Price Information for Creo Medical (CREO)

Share Price is delayed by 15 minutes
Get Live Data
13.50    0.00 (0.00%)
Bid:
13.25
Ask:
13.75
Spread: 0.50 (3.774%)
Market Cap: £65.58m
CREO Live PriceLast checked at - London Stock Exchange

Intraday Creo Medical Share Chart

Qingdao Marina Expansion

21 Jan 2008 08:44

China Real Estate Opportunities Ltd21 January 2008 China Real Estate Opportunities ("CREO" or the "Company") Further Qingdao Marina Expansion The Board of CREO is pleased to announce that, with Shanghai IndustrialInvestment Corporation ("SIIC"), the real estate investment arm of the ShanghaiMunicipal Government, it has acquired two sites in Tangdao Bay, Qingdao,adjoining the Company's existing development site, which was part of the initialportfolio acquired by CREO in 2007. Qingdao is the site of the sailing eventsfor the 2008 Beijing Olympics. The development is situated in a prime waterfront location within Huangdao, arising urban and leisure zone south of the Qingdao Central Business District,with which it is soon to be directly linked via a tunnel under Jiaozhou Bay,with an estimated travelling time of less than 20 minutes. CREO envisages the site as an integrated marina-based leisure resort withsignificant retail and residential elements for the increasing number ofvisitors and second home owners attracted by Qingdao's status as an exceptionaltourist destination. The plan is to develop the three sites as a single integrated project, with thecompleted development having a total gross floor area of 430,167 square metres,comprising residential, retail and hotel components with an estimated completionvalue in excess of RMB 5.5 billion (GBP360 million). CREO's acquisition cost for its 50 per cent. interest in the two sites will beapproximately £14.1 million, consisting of site acquisition, design,pre-development and infrastructure costs. An architectural firm has been engagedfor the first phase of the development, with work expected to commence during2008. Commenting on the acquisition, Richard David, Managing Director of TreasuryHoldings China Limited, CREO's investment manager, said: "This latest acquisition reaffirms CREO's strong commitment to both itspartnership with SIIC and the Qingdao market. With the infrastructure progressbeing made in Qingdao, and with the 2008 Olympics as the back-drop, CREO isoptimistic about its latest acquisition, which will complement the originaldevelopment." Enquiries to: CREO Ray Horney, ChairmanTel: + 44 (0)1273 775 225 Landsbanki Securities (UK) LimitedTel: + 44 (0)20 7426 9000Paul FinchamJonathan BecherRobert Naylor Bankside Consultants LtdTel: + 44 (0)20 7367 8888Simon RothschildOliver Winters Murray ConsultantsEd MicheauTel: + 353 1 498 0300 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
23rd Jun 20267:00 amRNSAppointment of Nominated Adviser /Corporate Broker
4th Jun 20267:00 amRNSPosting of 2025 Annual Report and Notice of AGM
28th May 20262:35 pmRNSHolding(s) in Company
22nd May 202610:11 amRNSResult of Placing
22nd May 20267:02 amRNSProposed Placing to raise approximately £5.5m
22nd May 20267:01 amRNSFY25 Final Results
22nd May 20267:00 amRNSProposed Sale of 49% Interest in Creo Medical SL
7th May 20267:00 amRNS-RMicroBlate™ Fine commercial update
5th May 20267:00 amRNS-RSpydrBlade™ Flex used in novel BEAM procedures
30th Apr 20267:00 amRNS-RKOL presentations on Creo Core Products at DDW
29th Apr 20267:00 amRNS-RUK private hospital use Speedboat for cancer case
22nd Apr 20267:00 amRNSPositive Q1 trading update
16th Apr 20267:00 amRNSDisposal and outsourcing of manufacturing
24th Feb 20267:00 amRNSAppointment of Joint Corporate Broker
20th Jan 20267:00 amRNSFY25 Trading Update
14th Jan 20267:00 amRNSAward of Shares under Share Incentive Plan
27th Oct 20257:00 amRNSNotice of Capital Markets Day
7th Oct 202511:37 amRNSCapital Markets Day update
22nd Sep 20257:00 amRNSUnaudited results for the six months ended 30 June
12th Sep 20253:14 pmRNSHolding(s) in Company
11th Sep 20257:00 amRNSNotice of Results
12th Aug 20254:56 pmRNSDirector/PDMR Share Dealing
4th Aug 20257:00 amRNS-RSpeedboat® patient testimonial
24th Jul 20257:00 amRNSAward of Shares under SIP and Director Dealings
21st Jul 20257:00 amRNSH1’25 Trading Update
10th Jul 20257:00 amRNS-RMicroBlate™ Flex begins lung tumour clinical study
9th Jul 20259:41 amRNSPDMR Options Revision
30th Jun 20257:00 amRNSChange of Nominated Adviser
26th Jun 202511:08 amRNSResult of AGM
26th Jun 20257:00 amRNSAGM Statement and Directorate Changes
11th Jun 20257:00 amRNS-RU.S. FDA clearance for SpydrBlade™ Flex
2nd Jun 20257:00 amRNSDirector/PDMR Shareholding
30th May 20257:00 amRNSPosting of AR&R and Notice of AGM
28th May 20257:00 amRNSUS Reimbursement milestone for Speedboat procedure
27th May 202512:48 pmRNSHolding(s) in Company
23rd May 20254:25 pmRNSHolding(s) in Company
22nd May 20257:00 amRNSDirectorate changes
19th May 20257:00 amRNSFinal Results
6th May 20257:00 amRNSNotice of investor presentations
15th Apr 20252:00 pmRNSNotice of Results
1st Apr 20259:34 amRNSHolding(s) in Company
31st Mar 202512:17 pmRNSHolding(s) in Company
26th Mar 20257:00 amRNSGrant of Options
20th Mar 20257:00 amRNS-RUK & EU Commercial launch of SpydrBlade™ Flex
6th Mar 20257:00 amRNSAppointment of Nominated Adviser and sole Broker
17th Feb 20257:00 amRNSFY24 Trading Update
12th Feb 202511:00 amRNSCompletion of sale of 51% interest in subsidiary
6th Feb 20259:00 amRNS-RFirst Welsh adopter of Speedboat® technology
3rd Feb 20253:00 pmRNSTotal Voting Rights
21st Jan 20257:00 amRNSAward of Shares under Share Incentive Plan

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.